Evidence map›Paper›PMID 25483425›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2015

Targeted therapy of colorectal neoplasia with rapamycin in peptide-labeled pegylated octadecyl lithocholate micelles.

Supang Khondee, Emily F Rabinsky, Scott R Owens, Bishnu P Joshi, Zhen Qiu, Xiyu Duan, Lili Zhao, Thomas D Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Supang KhondeeDepartment of Medicine, University of Michigan, Ann Arbor, MI, USA; School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand.
Emily F RabinskyDepartment of Medicine, University of Michigan, Ann Arbor, MI, USA.
Scott R OwensDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Bishnu P JoshiDepartment of Medicine, University of Michigan, Ann Arbor, MI, USA.
Zhen QiuDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Xiyu DuanDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Lili ZhaoDepartment of Statistics, University of Michigan, Ann Arbor, MI, USA.
Thomas D WangDepartment of Medicine, University of Michigan, Ann Arbor, MI, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA; Department of Mechanical Engineering, University of Michigan, Ann Arbor, MI, USA. Electronic address: thomaswa@umich.edu.
University of Michigan–Ann Arbor · USUniversity of Phayao · TH

Funding

University of Michigan Center for Gastrointestinal ResearchP30DK034933 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WILEY, JOHN W · 1986 to 2021
$22.5M
Small Animal Imaging CoreP50CA093990 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROSS, BRIAN D. · 2002 to 2012
$19.0M
Task Specific Project 4U54CA136429 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WANG, THOMAS D · 2008 to 2012
$5.2M
Targeted Multi-Spectral Dual Axes Confocal Imaging of In Vivo Molecular ExpressioR01CA142750 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KURABAYASHI, KATSUO, LUKER, GARY D · 2010 to 2014
$2.4M
NCI NIH HHS P50 CA093990NCI NIH HHS P50 CA93990NCI NIH HHS R01 CA142750NCI NIH HHS U54CA13642NCI NIH HHS U54 CA136429NIDDK NIH HHS P30 DK034933NIDDK NIH HHS P30 DK34933
6 · The paper itself

Abstract

Many powerful drugs have limited clinical utility because of poor water solubility and high systemic toxicity. Here, we formulated a targeted nanomedicine, rapamycin encapsulated in pegylated octadecyl lithocholate micelles labeled with a new ligand for colorectal neoplasia, LTTHYKL peptide. CPC;Apc mice that spontaneously develop colonic adenomas were treated with free rapamycin, plain rapamycin micelles, and peptide-labeled rapamycin micelles via intraperitoneal injection for 35days. Endoscopy was performed to monitor adenoma regression in vivo. We observed complete adenoma regression at the end of therapy. The mean regression rate for peptide-labeled rapamycin micelles was significantly greater than that for plain rapamycin micelles, P<0.01. On immunohistochemistry, we observed a significant reduction in phospho-S6 but not β-catenin expression and reduced tumor cell proliferation, suggesting greater inhibition of downstream mTOR signaling. We observed significantly reduced renal toxicity for peptide-labeled rapamycin micelles compared to that of free drug, and no other toxicities were found on chemistries. Together, this unique targeted micelle represents a potential therapeutic for colorectal neoplasia with comparable therapeutic efficacy to rapamycin free drug and significantly less systemic toxicity.

Indexed as

AdenomaAnimalsAntibiotics, Antineoplasticbeta CateninBinding, CompetitiveCell Line, TumorChemistry, PharmaceuticalColorectal NeoplasmsDrug Delivery SystemsHumansLithocholic AcidMiceMicellesPeptidesPolyethylene GlycolsSirolimusAntibiotics, Antineoplasticbeta CateninLithocholic AcidMicellesPeptidesPolyethylene GlycolsSirolimusColorectal cancerEndoscopyMicellesRapamycinTargeted therapy

Identifiers

PMID25483425
PMCPMC4308466
OpenAlexW2092181372

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.